ArticleApplied microbiology and biotechnology2022
Avermectin B1a production in Streptomyces avermitilis is enhanced by engineering aveC and precursor supply genes.
Article in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Functional Role of AveC Residues Ser138 and Ala139 for Avermectin and Doramectin Biosynthesis inMetabolites · 2026Article
- Scalable secondary metabolite production in Streptomyces using a plug-and-play system.Nature biotechnology · 2026Article
- CRISPR/Cas9-Mediated Polyketide Synthase Replacement for High-Yield Biosynthesis and Biological Activity of Milbemycin D.Biology · 2026Article
- A comprehensive review of genomic-scale genetic engineering as a strategy to improve bacterial productivity.Microbiology (Reading, England) · 2025Review
- Genome Combination Improvement Strategy Promotes Efficient Spinosyn Biosynthesis inJournal of agricultural and food chemistry · 2025Article
- Coordinated regulation of propionyl-CoA carboxylase subunits drives precursor flux optimization in spinosad production.Frontiers in microbiology · 2025Article
- Enhanced triacylglycerol metabolism contributes to the efficient biosynthesis of spinosad inSynthetic and systems biotechnology · 2024Article
- Metabolic engineering of Streptomyces roseosporus for increased production of clinically important antibiotic daptomycin.Microbial biotechnology · 2024Article
- Potential ofMetabolites · 2024Review
- Influence of Cluster-Situated Regulator PteF in Filipin Biosynthetic Cluster on Avermectin Biosynthesis inBiology · 2024Article
- Enhancement of acyl-CoA precursor supply for increased avermectin B1a production by engineering meilingmycin polyketide synthase and key primary metabolic pathway genes.Microbial biotechnology · 2024Article
- Novel strategy for depolymerization of avermectin fermentation residue to value-added amino acid product.Frontiers in chemistry · 2024Article
- Enhancing tylosin production by combinatorial overexpression of efflux, SAM biosynthesis, and regulatory genes in hyperproducingSynthetic and systems biotechnology · 2023Article
- Avermectin B1a Shows Potential Anti-Proliferative and Anticancer Effects in HCT-116 Cells via Enhancing the Stability of Microtubules.Current issues in molecular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avermectins (AVEs) are economically potent anthelmintic agents produced by Streptomyces avermitilis. Among eight AVE components, B1a exhibits the highest insecticidal activity. The purpose of this study was to enhance B1a production, particularly in the high-yielding industrial strain A229, by a combination strategy involving the following steps. (i) aveC gene was engineered to increase B1a:B2a ratio. Three aveC variants (aveC2m, aveC5m, and aveC8m, respectively encoding two, five, and eight amino acid mutations) were synthesized by fusion PCR. B1a:B2a ratio in A229 derivative having kasOp*-controlled aveC8m reached 1.33 (B1a and B2a titers were 8120 and 6124 μg/mL). Corresponding values in A229 were 0.99 and 6447 and 6480 μg/mL. (ii) β-oxidation pathway genes fadD and fadAB were overexpressed in wild-type (WT) strain and A229 to increase supply of acyl-CoA precursors for AVE production. The resulting strains all showed increased B1a titer. Co-overexpression of pkn5p-driven fadD and fadAB in A229 led to B1a titer of 8537 μg/mL. (iii) Genes bicA and ecaA involved in cyanobacterial CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.